Comparative Pharmacology
Head-to-head clinical analysis: CASODEX versus NILANDRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CASODEX versus NILANDRON.
CASODEX vs NILANDRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal antiandrogen that competitively inhibits the action of androgens by binding to cytosolic androgen receptors in target tissues, thereby blocking androgen-mediated gene expression and tumor growth. Does not suppress androgen production.
Competitive inhibitor of androgen binding to androgen receptors, reducing androgen-mediated growth of prostate cancer cells. Also inhibits testicular and adrenal androgen synthesis.
50 mg orally once daily
300 mg orally three times a day.
None Documented
None Documented
Terminal elimination half-life: 5-7 days (steady-state achieved in ~4 weeks); Long half-life due to high protein binding and slow tissue redistribution
Terminal elimination half-life: 7-8 hours; clinically relevant for twice-daily dosing.
Renal: <1% as unchanged drug; Fecal: ~83% as metabolites (mostly glucuronide conjugates); Biliary: significant as metabolites; Total clearance: 0.42 mL/min/kg
Renal: 55-60% as unchanged drug; fecal: 20-30% as metabolites; biliary: minor (<10%).
Category C
Category C
Antiandrogen
Antiandrogen